Core Viewpoint - A new treatment method developed by a research team led by Professor Xu Huji from the Second Affiliated Hospital of Naval Medical University has successfully improved the condition of a patient with refractory systemic sclerosis, demonstrating significant clinical transformation and improvement in key health indicators [1][3]. Group 1: Treatment Method and Results - The new treatment method has shown significant improvement in skin sclerosis and reversal of tissue fibrosis in the patient, along with notable enhancements in lung and heart functions [1][3]. - Systemic sclerosis is characterized by vascular abnormalities, immune activation, and progressive tissue fibrosis, presenting long-term treatment challenges due to limited drug efficacy and high disease heterogeneity [1][3]. Group 2: Cost and Future Implications - Current treatments like autologous hematopoietic stem cell transplantation or CAR-T cell therapy can cost up to 1 million yuan, while the new treatment method is expected to reduce costs to around 100,000 yuan once mass production is achieved [3]. - This research not only provides a new strategy for treating refractory systemic sclerosis but also validates the treatment concept of "targeted elimination" followed by "regenerative repair," opening new pathways for cell therapy in rheumatic diseases [3]. Group 3: Publication and Recognition - The case study titled "Application and Mechanism Study of iPSC-Derived Dual-Target CAR-NK Cells in Refractory Systemic Sclerosis" was published as an original article in the prestigious journal "Cell" on June 24 [4].